相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neuropeptide Y Y1 Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy
Juan Li et al.
ACS APPLIED MATERIALS & INTERFACES (2015)
Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults
S. Loschi et al.
BONE MARROW TRANSPLANTATION (2015)
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma
R. Tancredi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Ana Teresa Amaral et al.
CLINICAL CANCER RESEARCH (2015)
An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways
Valerie B. Sampson et al.
PLOS ONE (2015)
Neuropeptide Y receptors: a promising target for cancer imaging and therapy
Juan Li et al.
REGENERATIVE BIOMATERIALS (2015)
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
Edwin Choy et al.
BMC CANCER (2014)
A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study
Alberto S. Pappo et al.
CANCER (2014)
Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
Patrick J. Grohar et al.
CLINICAL CANCER RESEARCH (2014)
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Savita Sankar et al.
CLINICAL CANCER RESEARCH (2014)
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma
Cormac Owens et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112)
Patrick A. Thompson et al.
CLINICAL CANCER RESEARCH (2013)
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
P. Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2013)
The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models
Keith M. Wilcoxen et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Hae-June Lee et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma
Anna Raciborska et al.
PEDIATRIC BLOOD & CANCER (2013)
Optimal Management of Ewing Sarcoma Family of Tumors: Recent Developments in Systemic Therapy
Cormac Owens et al.
PEDIATRIC DRUGS (2013)
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
J. Chad Brenner et al.
CANCER RESEARCH (2012)
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Aung Naing et al.
CLINICAL CANCER RESEARCH (2012)
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Societe Francaise des Cancers et leucemies de l'Enfant et de l'adolescent (SFCE)
Veronique Minard-Colin et al.
EUROPEAN JOURNAL OF CANCER (2012)
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhab domyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group
Sylvain Baruchel et al.
EUROPEAN JOURNAL OF CANCER (2012)
Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma
Aleksandar Boro et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of Ganitumab, a Fully Human Anti-Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Richard B. Womer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma
Cecilia Garofalo et al.
MOLECULAR ENDOCRINOLOGY (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma
C. Mackintosh et al.
ONCOGENE (2012)
Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003
Elizabeth Fox et al.
ONCOLOGIST (2012)
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program
Christopher L. Morton et al.
PEDIATRIC BLOOD & CANCER (2012)
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Relja Popovic et al.
CANCER DISCOVERY (2012)
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
S. Ferrari et al.
ANNALS OF ONCOLOGY (2011)
Selective targeting of histone methylation
Abul B. M. M. K. Islam et al.
CELL CYCLE (2011)
Targeting of Insulin-Like Growth Factor Type 1 Receptor in Ewing Sarcoma: Unfulfilled Promise or a Promising Beginning?
Alan L. Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Risk of Recurrence and Survival After Relapse in Patients With Ewing Sarcoma
Martin Stahl et al.
PEDIATRIC BLOOD & CANCER (2011)
Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
Patrick J. Grohar et al.
NEOPLASIA (2011)
Angiogenesis and Vascular Targeting in Ewing Sarcoma A Review of Preclinical and Clinical Data
Steven G. DuBois et al.
CANCER (2010)
Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
Fei Huang et al.
CANCER RESEARCH (2010)
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis
Anna Rocchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Feasibility of bevacizumab (NSC 704865, BB-IN D# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study
P. Leavey et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan-Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors
Elizabeth Fox et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial
Ruth Ladenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility
Andrew Proctor et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience
Denise A. Casey et al.
PEDIATRIC BLOOD & CANCER (2009)
High expression of neuropeptide Y1 receptors in Ewing sarcoma tumors
Meike Koerner et al.
CLINICAL CANCER RESEARCH (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study
Julia L. Glade Bender et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The Differential Effects of the Radioprotectant Drugs Amifostine and Sodium Selenite Treatment in Combination with Radiation Therapy on Constituent Bone Cells, Ewing's Sarcoma of Bone Tumor Cells, and Rhabdomyosarcoma Tumor Cells In Vitro
Bryan S. Margulies et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2008)
DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells
E. Garcia-Aragoncillo et al.
ONCOGENE (2008)
EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma
Leah A. Owen et al.
PLOS ONE (2008)
Prognostic factors for local and distant control in Ewing sarcoma family of tumors
C. Rodriguez-Galindo et al.
ANNALS OF ONCOLOGY (2008)
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Mason Bond et al.
PEDIATRIC BLOOD & CANCER (2008)
Short telomeres: A novel potential predictor of relapse in Ewing sarcoma
Smadar Avigad et al.
CLINICAL CANCER RESEARCH (2007)
A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways
Hee-Jung Byun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells
T Kubo et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2006)
The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors
T Matsunobu et al.
CANCER RESEARCH (2006)
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing's sarcoma
K Scotlandi et al.
EUROPEAN JOURNAL OF CANCER (2006)
Transcriptional signature of ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
N Martínez et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1
R Ramakrishnan et al.
ONCOGENE (2004)
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3
A Prieur et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators
V Cerisano et al.
ONCOGENE (2004)
Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation
S Mateo-Lozano et al.
ONCOGENE (2003)
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
JZ Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone
HE Grier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study
RL Saylors et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF α and β receptor
DG Gilbertson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
PDGF-C is a new protease-activated ligand for the PDGF α-receptor
XR Li et al.
NATURE CELL BIOLOGY (2000)
Differential activation of MAP kinase family members triggered by CD99 engagement
MJ Hahn et al.
FEBS LETTERS (2000)
分享论文
